Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of rTMS in Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are a male or female aged 18 to 70 years.~* Have a diagnosis of Bipolar Disorder with a current ongoing episode of depression.~* Are not currently experiencing a mania.~* Have failed to achieve a clinical response or have been unable to tolerate an adequate dose of at least one of the medications used for treating Bipolar depression~* Are taking an anti-manic agent (lithium or valproate) or an atypical antipsychotic (quetiapine, lurasidone, aripiprazole, ziprasidone, risperidone, olanzapine), or a combination of the above, or a combination of any of them with lamotrigine 100-400 mg daily. Lamotrigine alone for bipolar II disorder is permitted.~* current medications have been at a stable dose in the 2 weeks prior to randomization~* Are capable of understanding, consenting to, and complying with the requirements of the study~Exclusion criteria:~* Have an alcohol or substance abuse or dependence within the last 3 months.~* Are at a significant risk of harm to themselves or others~* Are pregnant or planning on becoming pregnant in near future or lactating.~* Have a personal or family history of seizures.~* Have a history of unstable or inadequately treated medical illnesses, including moderate to severe brain injury or head trauma.~* Have a primary diagnosis of other psychiatric disorders (other than Bipolar) or personality disorders that are of primary concern and causing greater impairment other than bipolar disorder.~* are currently taking more than 3 of the antipsychotics.~* Have failed a course of ECT in the current episode.~* History of non-response to rTMS treatment.~* If participating in psychotherapy, you must have been in stable treatment for at least 3 months prior to entry into the study,~* Currently (or in the last 4 weeks) taking more than 2 mg daily (or equivalent) of lorazepam or any dose of medication for seizures~* Have a pacemaker, or an implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth that cannot be safely removed.~* Have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active iTBS rTMS (Type: ACTIVE_COMPARATOR): The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) daily for four weeks. The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
- Sham rTMS (Type: SHAM_COMPARATOR): sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues